Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y, et al. Breast cancer brain metastasis-overview of disease state, treatment options and future perspectives. Cancers (Basel) 2021;13:1078.

Dong Y, Tu R, Liu H, Qing G. Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat. Signal Transduct Target Ther. 2020;5:124.

Article  PubMed  PubMed Central  Google Scholar 

Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199–207.

Article  PubMed  CAS  Google Scholar 

Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102–4.

Article  PubMed  CAS  Google Scholar 

Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431:1112–7.

Article  PubMed  CAS  Google Scholar 

Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, et al. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. eLife. 2020;9:e50731.

Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun. 2022;13:6579.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Choi SK, Hong SH, Kim HS, Shin CY, Nam SW, Choi WS, et al. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms. Oncol Rep. 2016;35:1186–94.

Article  PubMed  CAS  Google Scholar 

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019;36:483–497.e415.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Braso-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016;22:1303–13.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One. 2013;8:e72967.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burkhart C, Fleyshman D, Kohrn R, Commane M, Garrigan J, Kurbatov V, et al. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget. 2014;5:11038–53.

Article  PubMed  PubMed Central  Google Scholar 

Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, et al. Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Sci Transl Med. 2011;3:95ra74.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Purmal AA, et al. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro-Oncol. 2017;19:186–96.

PubMed  CAS  Google Scholar 

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, et al. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med. 2015;7:312ra176.

Article  PubMed  PubMed Central  Google Scholar 

Nesher E, Safina A, Aljahdali I, Portwood S, Wang ES, Koman I, et al. Role of chromatin damage and chromatin trapping of FACT in mediating the anticancer cytotoxicity of DNA-binding small-molecule drugs. Cancer Res. 2018;78:1431–43.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang J, Sui Y, Li Q, Zhao Y, Dong X, Yang J, et al. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137. Cell Death Dis. 2020;11:1029.

Article  PubMed  PubMed Central  Google Scholar 

Leonova K, Safina A, Nesher E, Sandlesh P, Pratt R, Burkhart C, et al. TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. eLife 2018;7:e30842.

Chang HW, Nizovtseva EV, Razin SV, Formosa T, Gurova KV, Studitsky VM. Histone chaperone FACT and curaxins: effects on genome structure and function. J Cancer Metastasis Treat 2019;5:78.

Kantidze OL, Luzhin AV, Nizovtseva EV, Safina A, Valieva ME, Golov AK, et al. The anti-cancer drugs curaxins target spatial genome organization. Nat Commun. 2019;10:1441.

Article  PubMed  PubMed Central  Google Scholar 

Casey SC, Baylot V, Felsher DW. The MYC oncogene is a global regulator of the immune response. Blood. 2018;131:2007–15.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227–31.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell. 2017;171:1301–1315.e1314.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bernards R, Dessain SK, Weinberg RA. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell. 1986;47:667–74.

Article  PubMed  CAS  Google Scholar 

Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ, Schrier PI. c-myc down-regulates class I HLA expression in human melanomas. EMBO J. 1988;7:1023–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A, et al. Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. Sci Transl Med. 2014;6:217ra213.

Article  Google Scholar 

Raninga PV, Lee A, Sinha D, Dong LF, Datta KK, Lu X, et al. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics. 2020;10:5259–75.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res. 2005;3:1–13.

Article  PubMed  CAS  Google Scholar 

Chen M, Brackett CM, Burdelya LG, Punnanitinont A, Patnaik SK, Matsuzaki J, et al. Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy. Cancer Immunol, Immunother : CII. 2021;70:2073–86.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arvindam US, van Hauten PMM, Schirm D, Schaap N, Hobo W, Blazar BR, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia. 2021;35:1586–96.

Article  PubMed  CAS  Google Scholar